secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-058749
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023
---------------------------------------------------------------------------

- Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.
- NDA submission for etripamil (PSVT) to FDA remains on track for Q3 2023.
- Phase 2 ReVeRA trial (AFib-RVR) topline data expected H2 2023.
- Appointed Seth H.Z. Fischer to Board of Directors in March 2023.
- Operating loss of $15.0M in Q1 2023 vs. $14.0M in Q1 2022; R&D expense rose to $10.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/tm2315317d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-058749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer